

Accepted Manuscript

Brief report: Afatinib and cetuximab in four patients with *EGFR* exon 20 insertion positive advanced non-small-cell lung cancer

Bianca van Veggel, Adrianus J. de Langen, M.S. Sayed Hashemi, Kim Monkhorst, Daniëlle A.M. Heideman, Erik Thunnissen, Egbert F. Smit

PII: S1556-0864(18)30538-0

DOI: [10.1016/j.jtho.2018.04.012](https://doi.org/10.1016/j.jtho.2018.04.012)

Reference: JTHO 941

To appear in: *Journal of Thoracic Oncology*

Received Date: 10 January 2018

Revised Date: 8 March 2018

Accepted Date: 14 April 2018

Please cite this article as: van Veggel B, de Langen AJ, Hashemi S, Monkhorst K, Heideman DAM, Thunnissen E, Smit EF, Brief report: Afatinib and cetuximab in four patients with *EGFR* exon 20 insertion positive advanced non-small-cell lung cancer, *Journal of Thoracic Oncology* (2018), doi: 10.1016/j.jtho.2018.04.012.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article type

Brief report

Title

Brief report: Afatinib and cetuximab in four patients with *EGFR* exon 20 insertion positive advanced non-small-cell lung cancer

Authors list

Bianca van Veggel^a; Adrianus J. de Langen^b; Sayed M.S. Hashemi^c; Kim Monkhorst^d; Daniëlle A.M. Heideman^e; Erik Thunnissen^f; Egbert F. Smit^{a,c}

^aDept of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands b.v.veggel@nki.nl

^bDept of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands j.d.langen@nki.nl

^cDept of Pulmonary Diseases, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands s.hashemi@vumc.nl

^dDept of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, The Netherlands k.monkhorst@nki.nl

^eDept of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands dam.heideman@vumc.nl

^fDept of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands e.thunnissen@vumc.nl

Corresponding author

Prof Egbert F. Smit MD PhD, Dept of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands, tel: +31-20-5122958, e.smit@nki.nl

Disclosure

The authors have declared no conflicts of interest.

Funding

In one patient, cetuximab was provided free of costs by Merck Serono. No grant number is applicable.

Download English Version:

<https://daneshyari.com/en/article/8787551>

Download Persian Version:

<https://daneshyari.com/article/8787551>

[Daneshyari.com](https://daneshyari.com)